Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Aged
Antineoplastic Agents
/ therapeutic use
Carcinoma, Hepatocellular
/ diagnostic imaging
Embolization, Therapeutic
/ mortality
Female
Humans
Liver Neoplasms
/ diagnostic imaging
Male
Middle Aged
Prospective Studies
Radiation Dosage
Randomized Controlled Trials as Topic
Sorafenib
/ therapeutic use
Tomography, Emission-Computed
Torso
/ diagnostic imaging
Yttrium Radioisotopes
/ therapeutic use
Journal
Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
1
7
2020
medline:
16
12
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
Background Little is known about factors that influence the efficacy of transarterial radioembolization (TARE). Purpose To determine the relationship between tumor radiation-absorbed dose and survival and tumor response in locally advanced inoperable hepatocellular carcinoma treated with TARE. Materials and Methods This was a secondary analysis of prospectively acquired data (between December 2011 and March 2015) from participants who received TARE in the Sorafenib versus Radioembolization in Advanced Hepatocellular Carcinoma (SARAH) trial (ClinicalTrials.gov identifier: NCT01482442). Tumor-absorbed dose was computed using technetium 99m (
Identifiants
pubmed: 32602828
doi: 10.1148/radiol.2020191606
doi:
Substances chimiques
Antineoplastic Agents
0
Yttrium Radioisotopes
0
Yttrium-90
1K8M7UR6O1
Sorafenib
9ZOQ3TZI87
Banques de données
ClinicalTrials.gov
['NCT01482442']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
673-684Commentaires et corrections
Type : CommentIn